Le point sur la prise en charge de l’hyperpigmentation faciale
Peut-on utiliser autre chose que l’hydroquinone?
Résumé
Le profil multiculturel de l’Amérique du Nord est en train de changer. Aux États-Unis, la population des minorités visibles devrait atteindre 50% d’ici 2050. De même, au Canada, on prévoit que, au cours de la prochaine décennie, la couleur de la peau de près d’une personne sur trois au Canada correspondra aux phototypes IV à VI selon la classification de Fitzpatrick, alors que 60 % des résidents de Toronto et de Vancouver seront membres d’une minorité visible.
Bien que des troubles cutanés courants comme l’acné et la dermatite soient prévalents dans tous les groupes ethniques, certains problèmes, comme la dyschromie, sont plus facilement observables chez les patients ayant une peau plus foncée. Dans une étude comparant les dix diagnostics dermatologiques les plus fréquents chez les patients de race noire et les patients de race blanche aux États-Unis, les troubles de la pigmentation étaient la deuxième raison la plus fréquente pour laquelle les patients de race noire consultaient un dermatologue.
Références
Nijhawan RI, Jacob SE, Woolery-Lloyd H. Skin of color education in dermatology residency programs: Does residency training reflect the changing demographics of the United States? J Am Acad Dermatol. 2008;59(4):615-618.
Projections of the diversity of the Canadian population: 2006-2031. Statistics Canada; 2010. https://www150-statcan-gc-ca.myaccess.library.utoronto.ca/n1/pub/91-551-x/91-551-x2010001-eng.pdf. Accessed October 1, 2020.
Alexis AF, Sergay AB, Taylor SC. Common Dermatologic disorders in skin of color: A comparative practice survey. Cutis. 2007;80(5):387-394.
Dlova NC, Akintilo LO, Taylor SC. Prevalence of pigmentary disorders: A cross-sectional study in public hospitals in Durban, South Africa. International Journal of Women’s Dermatology. 2019;5(5):345-348.
Dermatology for skin of color. New York. McGraw-Hill. 2009.
Arsouze A, Fitoussi C, Cabotin PP, Chaine B. Presenting skin disorders in black Afro-Caribbean patients: a multicentre study conducted in the Paris region. Annales de dermatologie et de vénéréologie. 2008;135(3):177-182.
Ethnic dermatology principles and practice. Chichester, West Sussex. Wiley-Blackwell. 2013.
Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J. 2008;7(3):164-168.
Few JW. Cosmetic Dermatology for Skin of Color. Aesthetic Surgery Journal. 2010;30(2):275-276.
Lambert MW, Maddukuri S, Karanfilian KM, Elias ML, Lambert WC. The physiology of melanin deposition in health and disease. Clin Dermatol. 2019;37(5):402-417.
Alexis AF. New and emerging treatments for hyperpigmentation. J Drugs Dermatol. 2014;13(4):382-385.
Desai SR. Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014;7(8):13-17.
Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015;72(1):189-190.e181.
Dumbuya H, Grimes PE, Lynch S, et al. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals. J Drugs Dermatol. 2020;19(7):712-717.
Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009;13(4):183-191.
Zouboulis CC. Albert Montgomery Kligman—Remembering a Pioneer of Topical Treatment. JAMA Dermatology. 2017;153(1):65-65.
Woolery-Lloyd H, Kammer JN. Treatment of hyperpigmentation. Semin Cutan Med Surg. 2011;30(3):171-175.
Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75(1):57-62.
Bhawan JMDF, Grimes PMDF, Pandya AGMDF, et al. A Histological Examination for Skin Atrophy After 6 Months of Treatment With Fluocinolone Acetonide 0.01%, Hydroquinone 4%, and Tretinoin 0.05% Cream. American Journal of Dermatopathology. 2009;31(8):794-798.
Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010;62(6):962-967.
Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
Callender VD, Barbosa V, Burgess CM, et al. Approach to treatment of medical and cosmetic facial concerns in skin of color patients. Cutis. 2017;100(6):375-380.
Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-558.
Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials. J Drugs Dermatol. 2020;19(1):70-77.
Zubair R, Lyons AB, Vellaichamy G, Peacock A, Hamzavi I. What’s New in Pigmentary Disorders. Dermatol Clin. 2019;37(2):175-181.
Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. J Drugs Dermatol. 2007;6(9):917-922.
Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 5th ed: Elsevier; 2018.
Beauchêne C, Martins-Héricher J, Denis D, Martin L, Maillard H. [Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors]. Rev Med Interne. 2018;39(10):772-776.
Forbat E, Al-Niaimi F, Ali FR. The emerging importance of tranexamic acid in dermatology. Clin Exp Dermatol. 2020;45(4):445-449.
Perper M, Eber AE, Fayne R, et al. Tranexamic Acid in the Treatment of Melasma: A Review of the Literature. Am J Clin Dermatol. 2017;18(3):373-381.
Wang JV, Jhawar N, Saedi N. Tranexamic Acid for Melasma: Evaluating the Various Formulations. J Clin Aesthet Dermatol. 2019 Aug;12(8).
Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753-757.
Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. J Dermatolog Treat. 2018;29(2):182-189.
Cysteamine cream as a new skin depigmenting product. J Am Acad Dermatol. 2013;68(4 Supplement 1):AB189.
Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;173(1):209-217.
Kauvar AN. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med. 2012;44(2):117-124.
Lee HM, Haw S, Kim JK, Chang SE, Lee MW. Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin. Dermatol Surg. 2013;39(6):879-888.
Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatol Surg. 2018;44(6):814-825.
Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392.
Pattani A. A New Skin Lightening Procedure is Short on Evidence. The New York Times. 2017 August 28.
Dadzie OE. Unethical skin bleaching with glutathione. Bmj. 2016;354:i4386.
Dilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. J. 2019;18(3):728-737.
